OUR FOCUS
Committed to Successful Outcomes
One of the Healthcare industry’s most active subsectors, Biopharma draws strong corporate and investor interest in the development of novel medicines to treat significant unmet medical needs. Having a reliable, ongoing source of capital is key to funding the lengthy process of bringing therapies to market.
Investors and corporate clients repeatedly turn to Leerink Partners’ experience and expertise to unlock the growth potential of innovative biopharma companies.
Recent transactions
$150 Million
Financial Advisor
Placement and Entitlement Offering
July 2024
$130 Million
Lead Placement Agent
PIPE
July 2024
UNDISCLOSED
Financial Advisor
Asset Purchase Agreement with Genezen
July 2024
$350 Million
Co-Agent
At-The-Market (ATM) Facility
June 2024
